Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma

Ruth Pettengell, Hans E. Johnson, Pieternella J. Lugtenburg, Antonio Salar Silvestre, Ulrich Dührsen, Francesca G. Rossi, Matthias Schwenkglenks, Kate Bendall, Zsolt Szabo, Ulrich Jaeger

Research output: Contribution to journalArticle

Abstract

Purpose: This analysis from an observational study of clinical practice describes the impact of febrile neutropenia (FN) on chemotherapy delivery and hospitalizations. Methods: Adults with diffuse large B-cell lymphoma (DLBCL) scheduled to receive ≥3 cycles of 2- or 3-weekly CHOP with rituximab (R-CHOP-14/21) were eligible. Primary outcome was incidence of FN. Results: FN data were available for 409 patients receiving R-CHOP-14 and 702 patients receiving R-CHOP-21. FN incidence was R-CHOP-14, 20% (81/409) and R-CHOP-21, 19% (133/702). Rates of primary prophylaxis with granulocyte-colony stimulating factor were R-CHOP-14, 84% (345/409) and R-CHOP-21, 36% (252/702). A large number of patients experienced their first FN episode in cycle 1 (R-CHOP-14, 24/81 [30%]; R-CHOP-21, 63/133 [47%]). Multiple risk factors (≥2) for FN were more frequent in patients experiencing FN than in patients not experiencing FN (R-CHOP-14, 60/81 [74%] versus 179/328 [55%]; R-CHOP-21, 98/133 [74%] versus 339/569 [60%]). A similar trend was observed for unplanned hospitalizations (R-CHOP-14, 63/81 [78%] versus 68/328 [21%]; R-CHOP-21, 105/133 [79%] versus 100/569 [18%]). Achievement of chemotherapy relative dose intensity ≥90% was lower among patients experiencing FN than in patients not experiencing FN (R-CHOP-14, 30/81 [37%] versus 234/328 [71%]; R-CHOP-21, 83/133 [62%] versus 434/569 [76%]). Conclusions: In patients with DLBCL treated with R-CHOP-14 or R-CHOP-21, patients with an event of FN were more likely to experience suboptimal chemotherapy delivery and increased incidence of unplanned hospitalizations than those without FN. FN-related hospitalizations are likely to impact chemotherapy delivery and to incur substantial costs.

Original languageEnglish
Pages (from-to)647-652
Number of pages6
JournalSupportive Care in Cancer
Volume20
Issue number3
DOIs
Publication statusPublished - Mar 2012

Keywords

  • Chemotherapy dose intensity
  • Diffuse large B-cell lymphoma
  • Febrile neutropenia
  • G-CSF
  • Prophylaxis
  • R-CHOP

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Pettengell, R., Johnson, H. E., Lugtenburg, P. J., Silvestre, A. S., Dührsen, U., Rossi, F. G., Schwenkglenks, M., Bendall, K., Szabo, Z., & Jaeger, U. (2012). Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. Supportive Care in Cancer, 20(3), 647-652. https://doi.org/10.1007/s00520-011-1306-6